Abstract: Provided is a liquid crystal display panel including a thin-film transistor (TFT) array substrate and a first phase difference film. A liquid crystal layer is disposed between the TFT array substrate and the first phase difference film. A second phase difference film is disposed on the first phase difference film. A phase retardation value of the first phase difference film in a thickness direction is in a range of from about 100 nm to about 300 nm.

Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising amino acid sequence of SEQ ID NO:1, a fragment of any one sequence of SEQ ID NO:1, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Abstract: Provided are a hormone secretion modulator including a peptide derived from telomerase, more particularly, a peptide including an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having a sequence identity of at least 80% with SEQ ID NO: 1, or a fragment thereof, a pharmaceutical composition including the hormone secretion modulator, and a use of the pharmaceutical composition for treatment, alleviation, or prevention of diseases caused by excessive or deficient levels hormones.

Abstract: Methods are disclosed that are based on the finding that serum and plasma levels of eotaxin, MIP1?, and CRP act as important biomarkers that are useful for determining the feasibility in instigating immunotherapeutic treatment of cancer when immunizing with the GV1001 peptide (EARPALLTSRLRFIPK; derived from human telomerase protein), optionally when combined with state of the art combination treatment with Gemcitabine and Capecitabine. In particular, the present invention provides methods for determining whether patients should be treated GV1001 and for determining whether instigated treatment should be continued.

Abstract: The present disclosure relates to a composition for treating and preventing an ischemic injury. More particularly, it relates to a composition containing a peptide derived from a telomerase, which is effective in treating and preventing an ischemic injury. The peptide according to the present disclosure, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof, has a superior effect of treating and preventing an ischemic injury. Accordingly, a composition containing the peptide may be effectively used for an ischemic injury, particularly for an ischemic-reperfusion injury.

Abstract: Disclosed is a liquid crystal display device, including: first and second substrates, which are spaced apart from each other by a predetermined interval while facing each other; a reflective polarizing plate disposed under the first substrate, and including a first refractive index layer and a second refractive index layer, which have different refractive indexes and are repeatedly stacked; first and second compensation layers sequentially stacked on the second substrate, and an upper polarizing plate including a polarizing layer formed on the second compensation layer; and a liquid crystal layer formed between the first and second substrates.

Abstract: A display apparatus comprises a display panel, a first polarizing plate and a second polarizing plate. The display panel comprises a first substrate including a pixel electrode, a second substrate opposite to the first substrate, and a liquid crystal layer disposed between a first surface of the first substrate and a first surface of the second substrate. The first polarizing plate comprises a first polarizer having a first polarizing axis, and a first ?/4 phase difference plate having a refractive index between about 1.35 and about 2.05 in a thickness direction. The second polarizing plate comprises a second polarizer having a second polarizing axis crossing the first polarizing axis, and a second ?/4 phase difference plate having a refractive index between about 1.35 and about 2.05 in a thickness direction. Accordingly, light leakage in a side view may be reduced and viewing angle may be improved.

Abstract: Provided in the present invention is a peptide for preventing or treating sepsis. The peptide can improve symptoms of sepsis by inhibiting production of TNF, IL-1, and IL-6, which are cytokines that are related to sepsis, or can prevent or treat sepsis.

Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 6, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 6, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Abstract: The present invention relates to composition for preventing or treating cachexia, and more specifically, to a composition for preventing or treating cachexia containing a peptide derived from a telomerase. The composition for preventing or treating cachexia, according to present invention, has the advantages of improving symptoms of cachexia, such as weight loss, anemia, edema, and loss of appetite, and has few side effects.

Abstract: A liquid crystal display panel includes a first substrate, a second substrate facing the first substrate, a liquid crystal layer disposed between the first substrate and the second substrate, a first polarizing element disposed under the first substrate, the first polarizing element including a first polarizing layer and a second polarizing layer having different refractive indexes, the first polarizing layer having been stretched in a direction substantially parallel to a transmitting axis of the first polarizing element, and a second polarizing element disposed on the second substrate, the second polarizing element having been stretched in a direction substantially perpendicular to a transmitting axis of the second polarizing element.

Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Abstract: A display panel includes a first substrate, a second substrate facing the first substrate, a liquid crystal layer interposed between the first substrate and the second substrate, a first transparent conductive pattern disposed on a surface of the first substrate and including a plurality of openings, and a first polarizing member combined with the first transparent conductive pattern. The display panel may reduce bending due to contraction of the first polarizing member including a drawn polarizing layer. Furthermore, static electricity generated in the second substrate may be discharged thereby improving reliability of a display device including the display panel.

Abstract: A liquid crystal display panel includes a first base substrate, a wire grid polarizer disposed on the first base substrate, a lyotropic chromonic liquid crystal polarizer disposed on the first base substrate, a second base substrate facing the first base substrate and a liquid crystal layer between the first base substrate and the second base substrate.

Abstract: A liquid crystal display device includes a liquid crystal display panel which includes an array substrate including a pixel electrode, a gate line extending in a first direction and crossing the pixel electrode, and a data line extending in a second direction substantially perpendicular to the first direction, an opposing substrate including a common electrode in which a slit extending in the first direction and overlapping the gate line is defined, and a liquid crystal layer between the array substrate and the opposing substrate, and a light diffusion film which is disposed on the liquid crystal display panel and includes a plurality of low-refractive line members which respectively extends in the first direction and arranged in the second direction,

Abstract: A display apparatus including a first insulating substrate, a plurality of pixels, a second insulating substrate, a color filter layer, and a pattern retarder. The first insulating substrate includes a plurality of pixel areas arranged in an array of rows and columns, which has a length in the row direction longer than a length in the column direction, and has a length in a row direction longer than a length in a column direction. The pixels are arranged in the pixel areas, respectively, to display a 2D image and a 3D image. Among the pixels, first to fourth pixels successively arranged in the column direction define a unit pixel that displays one color information, and the fourth pixel corresponds to the white color pixel.

Abstract: A display apparatus including a display panel and a patterned retarder disposed on the display panel. The display apparatus displays a first image in a 2D mode and displays a second image including a left-eye image and a right-eye image in a 3D mode. Each of the sub-pixels included in the display panel includes two or three sub-pixel electrodes, and the patterned retarder includes a first retarder and a second retarder, which provide different directivities from each other to the left-eye image and the right-eye image, respectively. The first retarder is disposed corresponding to at least a portion of the sub-pixels and the second retarder is disposed corresponding to a remaining portion of the sub-pixels.

Abstract: The present disclosure relates to a composition for treating and preventing an rheumatoid arthritis, wherein the composition containing a peptide comprising amino acid sequence of SEQ ID NO: 1, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof. According to the present invention, provided is a composition for prevention or treatment of rheumatoid arthritis having a. superior effect of treating and preventing rheumatoid arthritis with minimized side effect.

Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.